Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

The extended chondrocyte lineage: implications for skeletal homeostasis and disorders.

Tsang KY, Cheah KS.

Curr Opin Cell Biol. 2019 Sep 18;61:132-140. doi: 10.1016/j.ceb.2019.07.011. [Epub ahead of print] Review.

PMID:
31541943
2.

Low-pass genome sequencing versus chromosomal microarray analysis: implementation in prenatal diagnosis.

Wang H, Dong Z, Zhang R, Chau MHK, Yang Z, Tsang KYC, Wong HK, Gui B, Meng Z, Xiao K, Zhu X, Wang Y, Chen S, Leung TY, Cheung SW, Kwok YK, Morton CC, Zhu Y, Choy KW.

Genet Med. 2019 Aug 26. doi: 10.1038/s41436-019-0634-7. [Epub ahead of print]

PMID:
31447483
3.

Synthesis and Evaluation of Imidazo[1,2-a]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3-Kinase Inhibitors.

Gamage SA, Spicer JA, Tsang KY, O'Connor PD, Flanagan JU, Lee WJ, Dickson JMJ, Shepherd PR, Denny WA, Rewcastle GW.

Chem Asian J. 2019 Apr 15;14(8):1249-1261. doi: 10.1002/asia.201801762. Epub 2019 Mar 12.

PMID:
30714356
4.

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.

Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY.

Cancer Biother Radiopharm. 2019 Apr;34(3):147-159. doi: 10.1089/cbr.2018.2628. Epub 2019 Jan 2.

5.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

6.

Mortality and morbidity of extremely low birth weight infants in Hong Kong, 2010-2017: a single-centre review.

Hon KL, Liu S, Chow JC, Tsang KY, Lam HS, So KW, Cheng YK, Leung AK, Wong W.

Hong Kong Med J. 2018 Oct;24(5):460-465. doi: 10.12809/hkmj177181.

7.

Inhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasia.

Wang C, Tan Z, Niu B, Tsang KY, Tai A, Chan WCW, Lo RLK, Leung KKH, Dung NWF, Itoh N, Zhang MQ, Chan D, Cheah KSE.

Elife. 2018 Jul 19;7. pii: e37673. doi: 10.7554/eLife.37673.

8.

Synergistic co-regulation and competition by a SOX9-GLI-FOXA phasic transcriptional network coordinate chondrocyte differentiation transitions.

Tan Z, Niu B, Tsang KY, Melhado IG, Ohba S, He X, Huang Y, Wang C, McMahon AP, Jauch R, Chan D, Zhang MQ, Cheah KSE.

PLoS Genet. 2018 Apr 16;14(4):e1007346. doi: 10.1371/journal.pgen.1007346. eCollection 2018 Apr.

9.

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.

Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM.

Front Immunol. 2018 Jan 4;8:1899. doi: 10.3389/fimmu.2017.01899. eCollection 2017.

10.

Coupling of lipid membrane elasticity and in-plane dynamics.

Tsang KY, Lai YC, Chiang YW, Chen YF.

Phys Rev E. 2017 Jul;96(1-1):012410. doi: 10.1103/PhysRevE.96.012410. Epub 2017 Jul 19.

PMID:
29347274
11.

Testing the Actions of a Multi-action Emollient: Patient's Acceptability Determines Product Efficacy.

Hon KL, Kung JSC, Tsang KYC, Yu JWS, Lee VW, Leung TF.

Curr Pediatr Rev. 2018;14(2):110-116. doi: 10.2174/1573396313666171117114005.

PMID:
29149811
12.

Change in Pneumococcus Serotypes but not Mortality or Morbidity in Pre- and Post-13-Valent Polysaccharide Conjugate Vaccine Era: Epidemiology in a Pediatric Intensive Care Unit over 10 Years.

Hon KL, Chan KH, Ko PL, Cheung MHY, Tsang KYC, Chan LCN, Chan RWY, Leung TF, Ip M.

J Trop Pediatr. 2018 Oct 1;64(5):403-408. doi: 10.1093/tropej/fmx084.

PMID:
29126217
13.

Activating the unfolded protein response in osteocytes causes hyperostosis consistent with craniodiaphyseal dysplasia.

Chan WCW, Tsang KY, Cheng YW, Ng VCW, Chik H, Tan ZJ, Boot-Handford R, Boyde A, Cheung KMC, Cheah KSE, Chan D.

Hum Mol Genet. 2017 Dec 1;26(23):4572-4587. doi: 10.1093/hmg/ddx339.

PMID:
28973168
14.

Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474.

Gamage SA, Giddens AC, Tsang KY, Flanagan JU, Kendall JD, Lee WJ, Baguley BC, Buchanan CM, Jamieson SMF, Shepherd PR, Denny WA, Rewcastle GW.

Bioorg Med Chem. 2017 Oct 15;25(20):5859-5874. doi: 10.1016/j.bmc.2017.09.025. Epub 2017 Sep 20.

PMID:
28958845
15.

Steroid phobia, Chinese medicine and asthma control.

Ip KI, Hon KL, Tsang KYC, Leung TNH.

Clin Respir J. 2018 Apr;12(4):1559-1564. doi: 10.1111/crj.12705. Epub 2017 Oct 12.

PMID:
28876537
16.

Immunoglobulin G4-related disease in Hong Kong: clinical features, treatment practices, and its association with multisystem disease.

Li PH, Ko KL, Ho CT, Lau LL, Tsang RK, Cheung TT, Leung WK, Lau CS.

Hong Kong Med J. 2017 Oct;23(5):446-53. doi: 10.12809/hkmj176229. Epub 2017 Sep 1.

17.

Do we need another symptom score for childhood eczema?

Hon KL, Kung JSC, Tsang KYC, Yu JWS, Cheng NS, Leung TF.

J Dermatolog Treat. 2018 Aug;29(5):510-514. doi: 10.1080/09546634.2017.1373734. Epub 2018 Jan 31.

PMID:
28849683
18.

Relevance of Cat and Dog Sensitization by Skin Prick Testing in Childhood Eczema and Asthma.

Hon KL, Tsang KYC, Pong NHH, Leung TF.

Curr Pediatr Rev. 2017;13(2):120-125. doi: 10.2174/1573396313666170615085018.

PMID:
28641549
19.

Emollient Acceptability in Childhood Atopic Dermatitis: Not All Emollients are Equal.

Hon KL, Kung JSC, Tsang KYC, Yu JWS, Lee VW, Leung TF.

Curr Pediatr Rev. 2018;14(2):117-122. doi: 10.2174/1573396313666170605080034.

PMID:
28578641
20.

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.

Rewcastle GW, Kolekar S, Buchanan CM, Gamage SA, Giddens AC, Tsang KY, Kendall JD, Singh R, Lee WJ, Smith GC, Han W, Matthews DJ, Denny WA, Shepherd PR, Jamieson SMF.

Oncotarget. 2017 Jul 18;8(29):47725-47740. doi: 10.18632/oncotarget.17730.

21.

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J.

Int J Cancer. 2017 Aug 1;141(3):583-593. doi: 10.1002/ijc.30767. Epub 2017 May 19.

22.

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.

23.

Clinical Signs, Staphylococcus and Atopic Eczema-Related Seromarkers.

Hon KL, Tsang KY, Kung JS, Leung TF, Lam CW, Wong CK.

Molecules. 2017 Feb 14;22(2). pii: E291. doi: 10.3390/molecules22020291.

24.

Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors.

Kendall JD, Giddens AC, Tsang KY, Marshall ES, Lill CL, Lee WJ, Kolekar S, Chao M, Malik A, Yu S, Chaussade C, Buchanan C, Jamieson SMF, Rewcastle GW, Baguley BC, Denny WA, Shepherd PR.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):187-190. doi: 10.1016/j.bmcl.2016.11.078. Epub 2016 Nov 25.

PMID:
27923617
25.

Mortality, length of stay, bloodstream and respiratory viral infections in a pediatric intensive care unit.

Hon KL, Luk MP, Fung WM, Li CY, Yeung HL, Liu PK, Li S, Tsang KY, Li CK, Chan PK, Cheung KL, Leung TF, Koh PL.

J Crit Care. 2017 Apr;38:57-61. doi: 10.1016/j.jcrc.2016.09.019. Epub 2016 Sep 30.

PMID:
27863269
26.

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.

27.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

28.

Urine Comprehensive Drug Screen, Low Birth Weight and Withdrawal Symptoms in a Neonatal Unit: A Case Control Study.

Hon KL, Chan MH, Ng MH, Ho CC, Tsang KY, Tam WH, Ho CS.

Curr Clin Pharmacol. 2016;11(4):274-281.

PMID:
27748174
29.

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.

Dominguez C, Tsang KY, Palena C.

Cell Death Dis. 2016 Sep 29;7(9):e2380. doi: 10.1038/cddis.2016.297.

30.

Revisit the Correlation between the Elastic Mechanics and Fusion of Lipid Membranes.

Fan ZA, Tsang KY, Chen SH, Chen YF.

Sci Rep. 2016 Aug 18;6:31470. doi: 10.1038/srep31470.

31.

Babesiosis acquired from a pet dog: a second reported case in Hong Kong.

Chan JM, Tsang KY, Chik TSh, Leung WS, Tsang OT.

Hong Kong Med J. 2016 Aug;22(4):393-5. doi: 10.12809/hkmj144390. No abstract available.

32.

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.

Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW.

Oncotarget. 2016 Jun 7;7(23):33498-511. doi: 10.18632/oncotarget.9256.

33.

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing.

Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):120-30. doi: 10.1016/j.ijrobp.2016.02.022. Epub 2016 Feb 13.

34.

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180.

35.

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, Schlom J.

Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.

36.

The impact of leukapheresis on immune-cell number and function in patients with advanced cancer.

Gulley JL, Marté J, Heery CR, Madan RA, Steinberg SM, Leitman SF, Tsang KY, Schlom J.

Cancer Immunol Immunother. 2015 Nov;64(11):1429-35. doi: 10.1007/s00262-015-1738-9. Epub 2015 Aug 5.

37.

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J.

Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.

38.

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Kwilas AR, Donahue RN, Tsang KY, Hodge JW.

Cancer Cell Microenviron. 2015;2(1). pii: e677.

39.

Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells.

Lu D, Graf RP, Harvey M, Madan RA, Heery C, Marte J, Beasley S, Tsang KY, Krupa R, Louw J, Wahl J, Bales N, Landers M, Marrinucci D, Schlom J, Gulley JL, Dittamore R.

J Circ Biomark. 2015 May 13;4:4. doi: 10.5772/60745. eCollection 2015 Jan-Dec.

40.
41.

Fate of growth plate hypertrophic chondrocytes: death or lineage extension?

Tsang KY, Chan D, Cheah KS.

Dev Growth Differ. 2015 Feb;57(2):179-92. doi: 10.1111/dgd.12203. Epub 2015 Feb 24. Review.

PMID:
25714187
42.

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.

Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Dec;63(12):1307-17. doi: 10.1007/s00262-014-1603-2. Epub 2014 Sep 4.

43.

Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation.

Yang L, Tsang KY, Tang HC, Chan D, Cheah KS.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12097-102. doi: 10.1073/pnas.1302703111. Epub 2014 Aug 4.

44.

Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.

45.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

46.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.

Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.

47.

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.

Vaccine. 2014 May 30;32(26):3223-31. doi: 10.1016/j.vaccine.2014.04.008. Epub 2014 Apr 13.

48.

The chondrocytic journey in endochondral bone growth and skeletal dysplasia.

Tsang KY, Tsang SW, Chan D, Cheah KS.

Birth Defects Res C Embryo Today. 2014 Mar;102(1):52-73. doi: 10.1002/bdrc.21060. Review.

PMID:
24677723
49.

WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.

Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C.

Cancer Res. 2014 May 1;74(9):2510-9. doi: 10.1158/0008-5472.CAN-13-1894. Epub 2014 Mar 13.

50.

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.

Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.

J Immunol. 2014 Mar 15;192(6):2622-33. doi: 10.4049/jimmunol.1301369. Epub 2014 Feb 10.

Supplemental Content

Loading ...
Support Center